weill-cornell
(5)
James K. Min
James K. Min is the founder and CEO of Cleerly, a Denver-based digital health company using AI to analyze coronary CT scans and detect atherosclerosis long before a heart attack strikes. A board-certified cardiologist who spent two decades in academic medicine, Min left a professorship at Weill Cornell and the directorship of the Dalio Institute of Cardiovascular Imaging to build a company that could deliver personalized, plaque-based heart evaluation at scale. He has authored more than 500 peer-reviewed papers, led landmark cardiac imaging trials, and raised hundreds of millions to push a shift from population-based cardiology toward individualized care.
Server Ertem
Server Ertem is the founder and CEO of Sanavia Oncology, a New York biotech developing antibody drug conjugates, T-cell engagers, and CAR-T therapies aimed at the roughly 80% of cancer patients whose tumors escape today's treatments. He built the company after a PhD in cancer cell biology at Weill Cornell, a postdoc at Memorial Sloan Kettering, and a Runway Startup Postdoc fellowship at Cornell Tech - stitching high-throughput cell biology, super-resolution microscopy, and machine learning into a platform designed to find cancer-specific epitopes on validated targets with atomic-level precision.
Jack O'Hara
Jack O'Hara is the co-founder and CEO of Translucent, an AI-native financial operating system for healthcare. After eight years running technology and transformation inside multi-billion-dollar provider organizations - including a stint as CIO at value-based care group ChenMed and CIO/Chief Transformation Officer at Springfield Clinic - he started Translucent in 2024 to give every hospital and medical group its own always-on AI financial analyst. The company pairs operational, clinical, and financial data into a single view that surfaces real-time insight and root-cause analysis. Translucent raised a $7M seed in August 2025 and a $27M Series A led by GV in March 2026.
Aditya Venugopal
Aditya Venugopal is the Chief Business Officer of Alentis Therapeutics, a clinical-stage Swiss biotech chasing first-in-class therapies aimed at claudin-1 for fibrosis and cancer. An immunologist turned dealmaker, he spent 15-plus years moving between the lab bench and the negotiating table: a Ph.D. in immunology from Weill Cornell, seven years in strategic life-science consulting, then senior roles at Intercept, VectivBio and Versanis Bio. He has a habit of being in the room when companies get acquired - VectivBio went to Ironwood, Versanis went to Eli Lilly - and he reunited with CEO Mark Pruzanski at Alentis after first partnering with him at Intercept.
Akili Hinson
Akili Hinson is the founder and CEO of Juno Medical, a technology-powered family medical practice he opened in Harlem in April 2020 with three patient rooms. A physician trained at Weill Cornell with an MBA from Columbia and a stint at McKinsey, he set out to build modern, family-centered primary care for what he calls 'the 99%' in neighborhoods that big health systems skip. Juno now runs clinics in Harlem, Brooklyn, East Atlanta, and Tulsa's Greenwood District, backed by a $12M Series A led by NEXT VENTURES and Serena Williams' Serena Ventures. He was named a 2024-2025 Obama Foundation USA Leader.